



UNIVERSITY OF HAWAI'I
CANCER CENTER

Pancreatic Cancer Biology and Medicine

Friday, February 15, 2019
12:00 noon



David Tuveson, M.D., Ph.D.
Director of the Cancer Center and
Roy J. Zukerberg Professor

Cold Spring Harbor Laboratory Cancer Center

Chief Scientist
Lustgarten Foundation

University of Hawai'i Cancer Center
701 Ilalo Street
Sullivan Conference Center
Light refreshments to follow

Curriculum vitae and Bibliography

Date of preparation: 02/07/2019

A. GENERAL INFORMATION

1. Name **David Tuveson**
2. Office address: 1 Bungtown Road
Cold Spring Harbor, New York 11724
Office telephone: 516-367-5246
Office fax: 516-367-8353
3. Email: dtuveson@csih.edu

B. EDUCATIONAL BACKGROUND

1. Degree(s)(Undergraduate and above), institution name and location, dates attended, and date(s) of degree(s) awarded (*in chronological order beginning with undergraduate degree or equivalent*)

<i>Degree</i>	<i>Institution name and location</i>	<i>Dates attended Mm/yy-mm/yy</i>	<i>Year Awarded</i>
B.S., Chemistry	Massachusetts Institute of Technology, Cambridge, MA	Sept. 1983 – Jun 1987	Jun. 1987
M.D.	Johns Hopkins University Baltimore, MD	Sept. 1987 – Jun. 1994	Jun. 1994
Ph.D.	Johns Hopkins University Baltimore, MD	Sept. 1987 – Jun. 1994	Jun. 1994

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

(In chronological order beginning with post-doctoral training positions: include full titles, ranks and inclusive dates held)

1. Post-doctoral training including residency/fellowship

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Internship, Internal Medicine	Brigham and Women's Hospital, Harvard Medical School, Boston, MA	Jun. 1994 - Jul. 1995
Resident in Internal Medicine, Fellow in Hematology/Oncology	Brigham and Women's Hospital Dana-Farber/Partners Cancer Care Harvard Medical School, Boston, MA	Jul. 1995 - Jun. 1997 Jul. 1997 - Jun. 2000
Postdoctoral fellow	Massachusetts Institute of Technology, Cambridge, MA	Jul. 1997- Jun. 2002

2. Academic positions (teaching and research)

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Instructor of Medicine, and Associate Physician	Harvard Medical School, Dana- Farber Cancer Institute and BWH Boston, MA	Jul. 2000- Jun. 2002
Assistant Investigator, and Assistant Professor of Medicine	Abramson Family Cancer Institute, University of Pennsylvania Philadelphia, PA	Jul. 2002- Aug. 2006
Senior Group Leader (with tenure)	Cambridge Research Institute Cambridge, UK	Sept. 2006- Aug. 2012
Professor of Pancreatic Cancer Medicine	Cambridge University Cambridge, UK	Apr. 2010 -
Professor, and Deputy Director of Cancer Center, and Director, Cancer Therapeutics Initiative	Cold Spring Harbor Laboratory Cold Spring Harbor, NY	Sept. 2012 –Dec 2016
Professor, and Director of Cancer Center	Cold Spring Harbor Laboratory	Dec 2016 -

3. Hospital positions (e.g., attending physician)

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Attending Physician	Hospital of the University of Pennsylvania, and VAH	Jul. 2002- Aug. 2006
Honorary Consultant, Oncology	Addenbrooke's NHS Hospital Cambridge, UK	Jun. 2009- Aug. 2012

4. Other Employment

<i>Title: Advisory Boards</i>	<i>Institution name and location</i>	<i>Dates</i>
Advisory Board Member Chair	Pancreatic Cancer Action Network,	Jan. 2005- Jan. 2012
	Pancreatic Cancer Action Network	Jul. 2010- Jan. 2012
	Pancreatic SSG, translational lead, Anglia UK	Jan. 2009- Aug. 2012
	Lustgarten Foundation of pancreatic cancer research	Jan. 2007- Jan. 2009
Chair	Board of Scientific Advisors, NCI	Sept. 2016-
	SAB, ESPAC-T, Liverpool, UK	Jan. 2010-2016
	Pancreatic Cancer Lead Advisor, Inspire to Live	Jan. 2011- Sept. 2013
	SAB, Cancer Research UK	Jan. 2011-2013
	Director of Research, Lustgarten Foundation (USA)	Jan. 2012-
	SAC, Stand Up to Cancer	Jan. 2012-
	SAB, Pancreatic Cancer UK	Jan. 2012-2016
	SAC, Georg-Speyer-Haus http://www.huntermtn.com/huntermtn/mountain/	Dec. 2013-

5. Breaks in academic or medically-related employment of one month or longer

N/A

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

<u>State</u>	<u>Number</u>	<u>Date of issue</u>	<u>Date of expiration</u>
Massachusetts	150467	1996	2002
Pennsylvania	MD421152	2003	
New York	268936	2013	
United Kingdom	7043722	2009	

	<u>Number</u>	<u>Date of issue</u>	<u>Date of expiration</u>
<u>DEA:</u>	FT4396203	03/06/14	11/30/2016
<u>NPI:</u>	1720016223	6/30/2006	5/4/2011

2. Board Certification(s)

<u>Full Name of Board</u>	<u>Candidate #</u>	<u>Year passed</u>	<u>Year expires/d</u>
PMETB in Medical Oncology (UK)		2009	
ABIM, Medicine Certificate	180340	1997	2007

ABIM, Medical Oncology Certificate 180340 2014 2024

E. PROFESSIONAL MEMBERSHIPS

<i>Member/officer/other</i>	<i>Name of Organization</i>	<i>Dates</i>
	American Association of Cancer Research	2003
	American Society of Clinical Oncology	2003
	American Gastroenterological Association	2005
	Massachusetts Medical Society	1994-2002
	American Society of Clinical Investigation	2016

F. HONORS AND AWARDS

<i>Name of award</i>	<i>Date awarded</i>
Medical Scientist Training Program Award	1987-94
Merck Index Award	1987
HHMI Physician-Scientist Training Award	1999
Forbeck Scholar Award	2000
AACR-PanCAN Career Development Award	2003
ML Smith Award, U Penn	2003
Rita Allen Foundation Scholar Award	2003
Manfred W. Comfort Memorial Lectureship, Mayo	2004
Frank P. Brooks Memorial Lectureship (APA)	2004
Norbert and Suzanne Schnog Lectureship, Yale	2005
Distinguished Visiting Professor of Pathology, JHU	2005
Ruth C. Brufsky Award, U Pittsburgh	2010
Dana-Farber/Harvard Palandjian visiting professor	2012
Dana-Farber Krackoff Family lectureship	2013
Jan Waldenstrom Award, Sweden	2014
Shanghai International Conference on Pancreatic Cancer, Chinese Society of Clinical Oncology in Shanghai, China	2014
American Society of Clinical Investigation	2016
Hamdan Award	2016

G. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation: None since moving back to the USA September 2012
Other Hospital Affiliations:
Other Institutional Affiliations:

H. EMPLOYMENT STATUS

Name of Employer(s): Cold Spring Harbor Laboratory

Employment Status: Full-time salaried

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND EFFORT

1. Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)

<i>Activity</i>	<i>Dates</i>
<u>Watson School for Biological Sciences, CSHL</u>	
Lecturer	2012-
<u>Teaching and clinical responsibilities at CRI and University of Cambridge:</u>	2010-
Lecturer, undergraduate Biochemistry parts 2 and 3	2009-2012
Attending and lead of Pancreatic Cancer Clinic	2006-2011
Lecturer PhD students: Cancer Biology and Medicinal Chemistry	
<u>International Teaching Course responsibilities in cancer research and medical oncology:</u>	
Faculty, AACR Molecular Biology in Clinical Oncology	2005-2016
Faculty, Jackson Lab Experimental models of Human Cancer	2010-
<u>Academic Committees at the University of Pennsylvania and Affiliated Hospitals:</u>	
Member, Preliminary Committee	2004-2006
U Penn MSTP selection committee	2002-2006
U Penn CAMB/MD-PhD selection committee	2003-2006
Tumor Biology committee	2003-2006
Cell Growth and Cancer selection committee	2004-2006
<u>Major Teaching and Clinical Responsibilities at the University of Pennsylvania:</u>	
Lecturer, CAMB 512 Cancer Genetics and Biology	
Lecturer, First year medical students hematology/oncology	
Attending in Fellows clinic 2003-2004	
Attending in Medical-Oncology clinic, VA Hospital	

Mentoring

Trainees – Post-Doctoral/Instructor:

1. Sunil Hingorani MD, PhD. (2002-2005). Professor, Fred Hutchinson, Seattle
2. Ken Olive PhD (2005-2009). Assistant Professor, Columbia University, New York
3. David Allard PhD (2006-2011). Group leader, Peninsula/Exeter Medical School, UK
4. Kris Frese PhD (2005-2012). Staff scientist, Manchester Christie Hospital
5. Albrecht Neesse, MD, PhD (2010-12). Attending Physician and Group Leader, University of Göttingen, Germany
6. Pedro Perez-Mancera, PhD (2004-2012). Group Leader, Liverpool University.
7. Christine Feig, PhD (2007-2012). Staff Scientist, CRI
8. Daniele Perna, PhD (2010-2012). Scientist, GSK, Cambridge UK
9. Christine Ardito, PhD (2013-2014). Amgen Corp.

10. Dannielle Engle, PhD (2011-). Current postdoc
11. Herve Tiriatic, PhD (2011-). Current postdoc
12. Chang-il Hwang, VMD, PhD (2012-8). Assistant Prof., UC Davis
13. Christine Chio, PhD (2012-7). Assistant Professor, Columbia U.
14. Erik Daniel Ohlund, MD, PhD (2012-6). Assistant Prof., Umea U.
15. Mariano Ponz Sarvise, MD, PhD (2013-5). Assistant Prof., Pamplona U.
16. Vincenzo Corbo, PhD (2013-5). Assistant Professor, Univ. Verona
17. Lindsey Baker, PhD (2013-). Research Scientist, CSHL
18. Mike Ludwig, PhD (2013-5). Biotech scientist
19. Ela Elyada, PhD (2013-). Current Postdoc
20. Mike Feigin PhD (2013-7). Assistant Prof., Roswell Park
21. Giulia Biffi PhD (2014 -). Current Postdoc
22. Koji Miyabayashi (2016-). Current Postdoc
23. Rintaro Koike (2018). Current Clinical Fellow
24. Dennis Plenker (2017-). Current Postdoc
25. Claudia Tonelli (2016 -). Current Postdoc
26. Fieke Froeling (2017-). Current Clinical Fellow

Trainees – Ph.D.:

1. Gina DeNicola (2005-2010), U Penn. Assistant Professor, Moffitt CC, FL
2. Florian Karreth (2004-2010), U Vienna. Assistant Professor, Moffitt CC, FL
3. Aarthi Gopinathan (2005-2010), U Penn. Staff, Cambridge pancreatic cancer center.
4. Meredith Caldwell (2006-2011), Cambridge U. Medical consultant.
5. Mike Jacobetz (2007-2011), Cambridge U. Scientist, Regeneron.
6. Natalie Cook (2007-2011), Cambridge U. Consultant Oncologist, Manchester Christie Hospital.
7. Timothy Humpton (2010-14), Cambridge U, Gates Fellowship.
8. Shivan Sivakumar (2010-14), Cambridge U. Oxford Consultant oncologist.
9. Abram Handly-Santana (2013-7), CSHL. Postdoc, Harvard.
10. Tobiloba Oni (2013-), SUNY Stony Brook.
11. Brinda Alagesan (2013-8), Stony Brook MD-PhD student.
12. Georgi Yordanov (2013-), CSHL
13. Derek Cheng (2014-), SUNY Stony Brook.
14. Jenifer Thalappillil (2017-), SUNY Stony Brook.

2. Clinical Care

<i>Activity</i>	<i>Dates</i>
Attending Physician at HUP and VAH, University of Pennsylvania. Patient care in the outpatient setting, and precepted medical oncology fellows	2002-6
Honorary Consultant (Attending Physician), Addenbrooke's Hospital, Cambridge UK. Patient care in the outpatient setting, and precepted medical trainees and junior doctors.	2009-12

Chief Investigator: Multicentre trial to evaluate 18F-FDG uptake by PET in patients with advanced pancreatic adenocarcinoma as an early indicator of drug activity (MK-0000). 5 trial sites included Cambridge Addenbrookes Hospital, Royal Marsden, Manchester Christie's Hospital, Mt. Vernon, and Liverpool. Opened April 2010, and closed in 2011 due to Merck shifting priorities. 15 patients accrued and analysis ongoing.

Chief Investigator: Investigator initiated, proof of mechanism biomarker study of an oral hedgehog inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period. Single site study of 15-20 patients opened 14 February 2011, closed August 2012 due to slow accrual and deprioritization of GDC0449.

Investigator, scientific Lead: A Cancer Research UK Phase I/IIa Trial of an Oral Notch Inhibitor (MK-0752) in Combination with Gemcitabine in Patients with Stage IV Pancreatic Cancer. Opened May 2010.

Onconet lead investigator, Cambridge. Multi-institute cooperative group experimental group, focused on oncology trials with Merck (~20 sites worldwide). Onconet discontinued by Merck.

3. Administrative duties

<i>Activity</i>	<i>Dates</i>
Member of Senior Leadership Council, CRI Cambridge UK	2008-2012
Deputy Director of Cancer Center, CSHL	2012-

4. Research

Pancreatic Cancer Biology and Medicine (since 2002)

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve students and/or researchers? (Y/N)</u>	<u>Does the activity involve trainees and/or researchers? (Y/N)</u>
Research/Teaching	90	NA	NA
Clinical Care	0		
Administration	10		
Research			
TOTAL	100%		

J. RESEARCH SUPPORT

ACTIVE

Title: NIH-NCI Administrative Supplement
 Dates: 08/17/16 – 07/31/21

Sponsor: NIH-NCI
Identification number: 5P30CA045508-31
Role: PI
Percent Effort: 30

Title: Integrated Translational Cancer Science Center
Dates: 06/12/14 – 02/28/20
Sponsor: NIH - NCI
Identification number: 5U10CA180944-05
Role: PI
Percent Effort: 10

Title: Principal Investigator
Dates: 07/01/18 – 06/30/23
Sponsor: Lustgarten Foundation
Identification number: NA
Role: PI
Percent Effort: 4

Title: Organoids Models of Pancreatic, Breast and Colorectal Cancer Model Development Ctr.
Dates: 01/09/17 – 04/30/19
Sponsor: Leidos Biomedical Research, Inc. / NCI
Identification number: N/A
Role: PI
Percent Effort: 4

Title: Targeting Pancreas Cancer
Dates: 03/06/17 – 03/05/21
Sponsor: The Thompson Family Foundation, Inc.
Identification number: N/A
Role: PI
Percent Effort: 1

Title: The Dedicated Lustgarten Laboratoy at CSHL
Dates: 09/01/17 -12/31/22
Sponsor: The Lustgarten Foundation
Identification number: N/A
Role: PI
Percent Effort: 14

Title: The Pancreatic Cancer Detection Consortium
Dates: 05/01/17 – 04/30/22
Sponsor: University of Nebraska Medical Center
Identification number: 1U01CA210240-01A1
Role: Co-PI
Percent Effort: 5

Title: Improving the Treatment of Pancreatic Cancer Patients with Organoids
Dates: 11/01/16 – 11/01/19
Sponsor: V Foundation – 2016 Translation Grant Program
Identification number: N/A
Role: PI
Percent Effort: 0

Title: Advanced Development and Validation of Three Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology
Dates: 08/01/16 – 07/31/19
Sponsor: NIH
Identification number: 1R33CA206949-01
Role: Co-PI
Percent Effort: 1

Title: NRF2 Regulation of Ductal Pancreatic Cancer Etiology & Treatment Response
Dates: 12/07/16-11/30/21
Sponsor: NIH
Identification number: 5R01CA188134-02
Role: PI
Percent Effort: 10

Title: Organoid Clinical Trials Proposal
Dates: 05/01/16 – 04/30/19
Sponsor: Lustgarten Foundation
Identification number: N/A
Role: PI
Percent Effort: 2

COMPLETED (within past three years)

Title: (PQA-4) Organoid Omics to Detect and Defeat Ductal Pancreatic Cancer
Dates: 09/22/14 – 08/31/18
Sponsor: NIH - NCI
Identification number: 5R01CA190092-04
Role: PI
Percent Effort: 10

Title: Proteomic Analyses of Extracellular Matrix in Pancreatic Cancer
Dates: 01/01/14 – 12/31/17
Sponsor: STARR Cancer Consortium
Identification number: I7-A718/STARR
Role: PI
Percent Effort: 0

Title: Pancreatic Organoids from EUS-guided Core Biopsy: Assembling a Living Biobank of Resectable and Nonresectable Pancreatic Cancers
Dates: 07/01/15 – 06/30/17
Sponsor: Stony Brook University/ASGE
Identification number: N/A
Role: Co-PI
Percent Effort: 0

Title: Genetic Heterogeneity of Pancreatic Cancer
Dates: 06/01/16 – 05/31/17
Sponsor: Hubrecht Institute
Identification number: SU2C-AACR-PS09
Role: PI
Percent Effort: 0

Title: Pancreatic Cancer Biology and Therapy
Dates: 9/01/15-12/31/17
Sponsor: Lustgarten Foundation
Identification number: NA
Role: PI
Percent Effort: 7

Title: Computational and Functional Approaches to Validating Cancer Genome Targets
Dates: 05/01/12 – 04/30/17
Sponsor: NIH
Identification number: 5U01CA168409-03
Role: Co-PI
Percent Effort: 5

Title: CSHL Cancer Center Support Grant Developmental Funds
Dates: 08/17/11 – 07/31/16
Sponsor: NIH-NCI
Identification number: 5P30CA45508-27
Role: Senior Leadership, Cancer Center, B. Stillman PI
Percent Effort: 10

Title: CSHL Cancer Center Support Grant Developmental Funds
Dates: 08/17/11 – 07/31/16
Sponsor: CSHL Association
Identification number: N/A
Role: Start up support
Percent Effort: 10

MENTEE AWARDS

Florian Karreth Ph. D. student trainee, recipient of AACR award “Future Leader in Cancer Research, 2010”

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

(e.g., Invited lectures, Journal reviewer, NIH study section, etc)

Invited lectures

<i>Date</i>	<i>Lecture and venue</i>
March 19-24, 2003	“BRAF as a potential therapeutic target in malignancy”. Keystone Symposia. Molecular targets for Cancer therapy. Banff, Canada
May 3, 2003	“An oncogenic K-ras mouse model of early ductal pancreatic neoplasia (PanIN)”. UCSF Cancer Center. San Francisco, CA
May 16-18, 2003	“Modeling exocrine pancreatic cancer in mice”. Third Euroconference on animal models of human diseases. Prague
June 23, 2003	“Targeting Raf in Melanoma”. First International Melanoma Research Congress. Philadelphia, PA
September 10, 2003	“Conditional expression of an endogenous KRAS oncogene induces murine PanIN.” Pancreatic Development and Disease Modeling Conference. Chicago, IL
November 12, 2003	“Modeling exocrine pancreatic cancer in mice”. Peter MacCallum Cancer Center Symposia. Melbourne, Australia
December 17, 2003	“Modeling Ductal Pancreatic Cancer in Mice”. Eppley Cancer Institute at University of Nebraska, Omaha, NE
January 21-24, 2004	“Preclinical models of pancreatic cancer”. 2004 GI symposium: Current Status and Future Directions for Prevention and Management. San Francisco, CA
March 18, 2004	“Oncogenic KRAS initiates tumorigenesis.” Yale University, Department of Pathology Grand Rounds. New Haven, CT
March 27, 2004	“Early and advanced ductal pancreatic cancer in mice.” AACR annual meeting, Symposium on mouse modeling, Orlando, FL
April 20, 2004	“Ras/Raf oncogenesis and intervention.” David H. Rittenberg Cancer Center seminar at Mt. Sinai University, New York, NY
May 3, 2004	“V599E BRAF as an Oncogene in Melanoma.” Penn State University, Hershey Medical Center: Third annual mini-symposium on Melanoma. Hershey, PA
May 10, 2004	“Oncogenic Kras as an initiating event in neoplasia.” Hutchison/MRC centre at the University of Cambridge, UK
May 11, 2004	“Oncogenic Kras as an initiating event in neoplasia.” The Wellcome Trust Sanger Institute, Hinxton, UK
May 12, 2004	“Oncogenic Kras as an initiating event in tumorigenesis.” The Imperial Cancer Research Foundation, London, UK
May 13, 2004	“Ras signaling in mouse cancer models.” The Josephine Nefkens Institute, Erasmus Medical College University Medical Center, Rotterdam, Holland
May 14, 2004	“Ras signaling in mouse cancer models.” The Netherlands Cancer Institute, Amsterdam, Holland

June 14, 2004 “Modeling ductal pancreatic cancer in mice.” Third EDNR Scientific Workshop, Bethesda, MD

June 25, 2004 “Modeling ductal pancreatic cancer in mice.” Lustgarten/AACR Annual meeting, San Francisco, CA

August 1, 2004 “The KRAS oncogene initiates neoplasia.” Gordon Research Conference on Cancer: Models & Mechanisms. Newport, RI

October 4, 2004 “Modeling ductal pancreatic cancer in mice.” University of Arizona Cancer Center, Tucson, AZ

October 11, 2004 “Modeling ductal pancreatic cancer in mice.” Manfred W. Comfort Memorial Lectureship in Gastroenterology. Mayo Cancer Center, Rochester, MN

October 12, 2004 “Ras oncogenesis.” University of Minnesota Cancer Center. Minneapolis, MN

November 4, 2004 “Early and advanced ductal pancreatic cancer mouse models.” American Pancreatic Association, Frank P. Brooks Memorial Basic Science state-of-the-art lecture, Chicago, IL

November 8, 2004 “Mouse models of pancreatic cancer.” International conference of Tumor Progression and Therapeutic Resistance. Philadelphia, PA

November 16, 2004 “Analysis of oncogenic BRAF function.” Second annual Melanoma Research Congress. Phoenix, AZ

November 19, 2004 “Oncogenic Kras induces cancer.” University of Michigan Cancer Center annual fall symposium. Ann Arbor, MI

December 8, 2004 “Ras/Raf oncogenesis and therapy.” Skirball Institute, New York University. New York, NY

January 5, 2005 “RAF/RAS oncogenes and therapy.” Cancer Institute of New Jersey. New Brunswick, NJ

January 14, 2005 “Modeling and manipulating cancer.” Georgetown University Lombardi Cancer Center. Washington, DC

January 22, 2005 “Mouse models of early and advanced ductal pancreatic cancer.” ISREC conference, Lausanne, Switzerland

February 3, 2005 “Modeling and manipulating cancer.” Kimmel Cancer Center at Thomas Jefferson University. Philadelphia, PA

February 9, 2005 “Ras/Raf pathway in Cancer Biology and Therapy.” Wistar Institute lecture series. Philadelphia, PA

March 2, 2005 “Modeling and manipulating cancer.” Johns Hopkins Cancer Center Translational Research Conference. Baltimore, MD

March 17, 2005 “Mouse models of ductal pancreatic cancer.” 7th Charles Rodolphe Brupbacher Symposium. ETH Zurich, Switzerland

April 20, 2005 “Novel animal models for pancreatic cancer.” AACR, pancreatic cancer minisymposium. Anaheim, CA

April 26, 2005 “Modeling ductal pancreatic cancer in mice.” Norbert and Suzanne Schnog lecture. Yale University Cancer Center Grand Rounds, New Haven, CT

May 4, 2005 “Modeling and manipulating cancer.” Lineberger Cancer Center grand rounds, UNC. Chapel Hill, NC

May 16, 2005 “Translational studies in melanoma.” ASCO, Orlando FL

May 17, 2005 “Modeling ductal pancreatic cancer in mice.” AGA, Chicago, I.

June 2, 2005 “p53R172H and KrasG12D cooperate to induce CIN and metastatic ductal pancreatic adenocarcinoma in the mouse.” Cold Spring Harbor Symposium, Cold Spring Harbor, NY

June 6, 2005 “Mouse models of ductal pancreatic cancer.” Mayo clinic, Rochester, MN

June 15, 2005 “Oncogenic Kras induces pancreatic cancer.” Gordon Research Conference, Hong Kong

June 22, 2005 “p53R172H and KrasG12D cooperate to induce CIN and metastatic ductal pancreatic adenocarcinoma in the mouse.” Beatson International Cancer Conference, Glasgow, Scotland.

August 15, 2005 “Mouse models of ductal pancreatic cancer.” FASEB, Snowmass

September 12, 2005 “Pancreatic cancer: from models to medicine”. Johns Hopkins University distinguished visiting professor of pathology.

September 30, 2005 “Modeling and manipulating cancer”. Memorial Sloan Kettering Cancer Center, Cancer Biology and Genetics seminar. New York, NY

October 4, 2005 “Advances in modeling pancreatic cancer.” NCRI cancer conference, Birmingham, UK

October 28, 2005 “Modeling and manipulating cancer.” MAPs meeting, Wistar Institute, Philadelphia, PA

November 3, 2005 “A prototypic mouse hospital for preclinical testing.” NFI and NF2 meeting, CSHL Banbury conference center, Cold Spring Harbor, NY.

November 22, 2005 “Modeling and manipulating pancreatic cancer.” Dana Farber Cancer Institute, Boston, MA

January 27, 2006 “Mouse models of pancreatic cancer.” GI cancer symposium. San Francisco, CA

February 2, 2006 “Modeling and manipulating ductal pancreatic cancer in mice.” Netherlands Cancer Institute. Amsterdam, the Netherlands

February 14, 2006 “Ductal pancreatic cancer in mice.” Burnham Institute. San Diego, CA

February 24, 2006 “Animal models of pancreatic cancer.” Thomas Jefferson University, annual symposium at KCC. Philadelphia, PA

June 26, 2006 “Pancreatic cancer preclinical therapeutic investigations.” Lustgarten symposium, Chapel Hill, NC

November 13, 2006 “Transgenic models of human pancreatic cancer”. AACR, Boston, MA

March 7, 2007 “Pancreatic cancer models and medicine”. UCLA Pharmacology lecture series, Los Angeles, CA

March 9, 2007 “Pancreatic cancer modeling”. Moffitt cancer center, Tampa, FL.

March 14, 2007 “Pancreatic cancer models and medicine”. University of Manchester, UK

April 2, 2007 “Pancreatic cancer models and medicine”. Transregio Ras conference, Rothenberg, Germany

April 14, 2007 “Pancreatic cancer medicine in mice.” AACR symposia Los Angeles, CA

May 7, 2007 “Pancreatic cancer models and medicine.” Biomedicum Helsinki, Finland

June 15, 2007 “Pancreatic cancer medicine”. Pezcoller Foundation, Trento, Italy

September 10, 2007 “Pancreatic cancer models and medicine.” Beatson Conference, Glasgow

October 2, 2007 “Pancreatic cancer models and medicine.” Plenary Lecture, NCRI, Birmingham, UK

November 29, 2007 “Pancreatic cancer models and medicine.” CGC workshop, Utrecht, NE

May 7, 2007 “Pancreatic cancer models and medicine.” Biomedicum Helsinki, Finland

March 8, 2008	“Pancreatic cancer models and medicine.” ISCO congress, Amsterdam.
March 28, 2008	“Pancreatic cancer models and medicine.” ISREC, Lausanne, Switzerland.
April 12, 2008	“Pancreatic cancer models and medicine.” AACR, San Diego, CA
May 14, 2008	“Pancreatic cancer models and medicine.” St. George’s Hospital, London.
May 30, 2008	“Pancreatic cancer models and medicine.” CNIO, Madrid, Spain
June 25, 2008	“Modeling pancreatic cancer in mice”. EPC. Ludz, Poland
July 4, 2008	“Pancreatic ductal cancer in mice”. IMP, Vienna, Austria
July 27, 2008	“Using the mouse to model pancreatic cancer”. Keynote speaker, Gordon Research Conference, Smithfield Rhode Island, USA
September 9, 2008	“Pancreatic Cancer Models”, BSCB, London
October 9, 2008	“Modeling Pancreatic Cancer in Mice”, SEMM, Milan Italy
October 19, 2008	“Pancreatic Cancer Models and Medicine”, Translational Research in Oncology Symposium, Los Angeles, CA
November 13, 2008	“Pancreatic Cancer Models and Medicine”, MDACC, Houston, TX
November 18, 2008	“Mouse Models to Prevent and Treat Cancer”, AACR Prevention Meeting, Washington, DC
November 28, 2008	“Modeling Pancreatic Cancer”. CGC/CBG meeting, Amsterdam.
January 15, 2009	“Pancreatic Cancer Medicine in Mice”, AACR Mouse Models of Cancer Conference. San Francisco, CA
January 16, 2009	“Pancreatic Cancer: Animal Models”, Salk Institute. La Jolla, CA
March 11, 2009	“Pancreatic cancer models and medicine”, Leeds, UK
March 20, 2009	“Pancreatic Cancer models and medicine”, AEK Congress, Berlin
April 7, 2009	“Pancreatic Cancer Models and Medicine”, Dundee Biomedical Research Institute
April 18-22, 2009	“Therapeutic targeting of Ras Pathway” 4/18; “Pancreatic Cancer Models and Medicine” 4/20; “Biology and therapy of K-ras initiated pancreatic cancer in mice” 4/21, Denver
May 23, 2009	“Pancreatic Cancer Models and Medicine”, Abruzzo Symposia, Fara San Martino, Italy
May 29, 2009	ASCO discussant: “AMG655/gemcitabine for pancreatic cancer” Orlando, FL
June 8, 2009	“Pancreatic cancer models and medicine”, CNIO, Madrid
June 18, 2009	“Animal Models of Pancreatic cancer”, CIOCC, Madrid
July 10, 2009	“Mouse Models of Pancreatic cancer”, Loewes symposia, Marburg
August 24, 2009	“Cancer treatment strategies” Jackson Laboratory, Maine
September 16, 2009	“Developing Pancreatic cancer”, Stem Cells and Cancer Gordon Conference, Les Diablerets, Switzerland
September 23, 2009	“Ras in cell transformation and senescence”, ECCO Berlin
October 20, 2009	“Pancreatic Cancer Models and Medicine” University of Tokyo, Japan
October 22, 2009	“Pancreatic Cancer Models and Medicine”, Biochemical Society Meeting, Kobe, Japan
October 23, 2009	“Cancer Models and Medicine”, University of Kyoto
December 16, 2009	“Modeling and Manipulating Cancer”. Baylor University, Houston, Texas
January 14, 2010	“Ras Oncogenesis” University of Vienna
January 20, 2010	“Modeling Pancreatic Cancer in Mice: K-Ras oncogene-induced ROS detoxification promotes tumorigenesis”. Manchester Cancer Centre Inaugural Meeting, Manchester, UK

January 23, 2010	GI Oncology Meeting, Orlando FL. "Drug Delivery in Pancreatic Cancer"
January 28, 2010	"Pancreatic Cancer Models and Medicine" UK HPB-ALPS meeting, Madonna di Campiglio, Italy
February 18, 2010	"Pancreatic Cancer Medicine", CHUV-Lausanne, CH
February 19, 2010	"Models and Medicine of Cancer", EPFL/ISREC, Lausanne CH
March 1, 2010	"Cancer Models and Medicine" University of Queensland
March 17, 2010	"Pancreatic Cancer Models and Medicine", University of Birmingham Cancer Centre
March 23, 2010	"Pancreatic Cancer Oncogenesis" British Society of Gastroenterology, Liverpool, UK
April 14, 2010	"Cancer Models and Medicine", Cold Spring Harbor Lab, NY
April 20, 2010	"Pathways Promoting Pancreatic Cancer", AACR, Washington DC
April 22, 2010	"Modeling Cancer to Develop Medicines", Ontario Cancer Institute, Toronto
April 30, 2010	"Developing Pancreatic Cancer Medicines" London Pancreatic Society Meeting
May 7, 2010	"Modeling Carcinoid in Mice", Cambridge, USA
May 19, 2010	"Developing Pancreatic Cancer Medicines", Curie Institute, Paris
June 11, 2010	"Oncogenic Kras: Models and Medicine" MIT Koch Institute symposium, Cambridge, MA
June 15, 2010	"Pancreatic cancer models and medicine", BACR, Edinburgh, UK
June 19, 2010	"Developing Pancreatic Cancer Medicines", European Pancreatic Cancer society meeting, Stockholm, Sweden
July 29, 2010	"What Mice Teach Men about Pancreatic Cancer". Ruth Brufsky Award, PancreasFest 2010. University of Pittsburgh, USA
August 23, 2010	"Cancer Treatment Strategies". Jackson Labs, Bar Harbor, Maine
September 9, 2010	"Models to Develop Pancreatic Cancer Medicine". Les Treilles, FR
September 29, 2010	"Tumour Microenvironment Promotes Therapeutic and Immune Resistance in Pancreatic Cancer". MIT Cancer Center.
October 8, 2010	"Modeling Pancreatic Cancer Medicine". ICC, Barcelona, Spain
November 4, 2010	"Tumor-Host Interactions and Angiogenesis: Developing Pancreatic Cancer Medicine". Monte Verita, Ascona, Switzerland
November 9, 2010	"Developing Pancreatic Cancer Medicine". NCRI, Liverpool, UK
March 11, 2011	"Modeling Pancreatic Cancer Treatment". Karolinska Inst, Sweden
March 16, 2011	"Developing Pancreatic Cancer Medicine". Patterson Institute, UK
March 21, 2011	"Models for Pancreatic Cancer Medicine". Vanderbilt, USA
March 23, 2011	"Stromal barriers in Pancreatic Cancer Medicine". Banbury/CSHL, NY
April 2, 2011	"Modeling pancreatic cancer metastasis in mice". AACR, Orlando
April 5, 2011	"Developing Pancreatic Cancer Medicines in Mouse Models", AACR Orlando, FL
May 7, 2011	"Translating Mouse Models of Pancreatic Cancer to Humans", DDW, Chicago, USA
June 3, 2011	"Controlling oncogenic Kras transformation", Berlin, DE.
June 25, 2011	EPC lecture, "Cell death in experimental tumor models" Madgeburg, Germany
June 30, 2011	"Modeling Cancer and its treatment", UCL, London
July 8, 2011	"Developing Pancreatic Cancer Medicine", UCSF, US

July 11, 2011	“Malignant Transformation of Pancreatic Cells”. CMTRA, Asilomar, CA
July 28, 2011	“Usp9x is a novel tumour suppressor in ductal pancreatic cancer”. SPORE meeting, Washington, DC
July 31, 2011	“Oncogenic Kras tumorigenesis”. GRC, Bates College Maine
August 10, 2011	“Usp9x is a novel tumour suppressor in ductal pancreatic cancer”. Salk Institute
August 11, 2011	“Developing Pancreatic Cancer Medicine” Scripps Institute, USA
February 7, 2012	“Pancreatic Cancer Medicine” NKI Symposium for Anton Berns.
February 27, 2012	“Improving Animal Models” MDACC
March 12, 2012	“Using Mice to inform us about human Pancreatic Cancer”, Ipsen Conference, Ouro Preto, Brazil
March 26, 2012	“Preclinical Drug Development in Pancreatic Cancer”, Kalandjian Lectureship, DFCI
March 27, 2012	“Pancreatic Cancer Biology and Medicine” Dana-Farber/PCC Grand Rounds
March 30, 2012	“Pancreatic Cancer Modeling”, University of Chicago
April 2, 2012	“Pancreatic Cancer Biology and Medicine”, Chicago, AACR
April 5, 2012	“Pancreatic Cancer Biology & Therapy”, AFCRI at U Penn
May 9, 2012	“Pancreatic Cancer Therapeutic Strategies” Pfizer. San Diego, CA
May 10, 2012	“Developing therapeutics in mice with ductal pancreatic cancer” AACR, San Diego, CA
August 20, 2012	“Pancreatic Cancer”, University of Toronto, Canada
January 8, 2013	“Pancreatic Cancer Biology and Medicine”, MDACC, Houston, TX
February 15, 2013	“Pancreatic Cancer Biology and Medicine” CRCL, Lyon, FR
Feb 27, 2013	“Detecting pancreatic cancer”, AACR San Diego CA
March 21, 2013	“Can Mouse models improve clinical medicine?”, ISREC distinguished lectureship, Lausanne, CH
April 6, 2013	“Stromal targeting approaches in mouse Pancreatic Cancer”, AACR, Washington, DC.
May 1, 2013	“Developing better treatments for Cancer”, Helen Rollason lecture, Glasgow, UK
May 4, 2013	“Pancreatic Cancer Biology and Medicine”, DFG, Lake Como, Italy
May 15, 2013	“Developing better treatments for Pancreatic Cancer”, Vanderbilt University, Nashville, TN
May 21, 2013	“Pancreatic Cancer Biology and Therapy”, Stanford
June 12, 2013	“Pancreatic Cancer Detection and Treatment”, HICC Columbia symposium
June 25, 2013	“Developing Better Treatments for Pancreatic Cancer”, Krackoff Family Lectureship, Dana-Farber, Boston MA
July 5, 2013	“Molecular Changes in Pancreatic Cancer”, ESMO Keynote, Barcelona, SP
July 8, 2013	“Tumor Microenvironment determines therapeutic response in pancreatic cancer”, Beatson Conference, Glasgow UK
July 12, 2013	“MD-PhD Programs in the USA and fixing Pancreatic Cancer”, MCW, WI USA
July 15, 2013	“GEMM as models for targeted drug discovery and evaluation in Pancreatic Cancer”, CMTRA, Boulder CO
August 22, 2013	“Nrf2 promotes Pancreatic Cancer”, Gordon Conference, Proctor NH

September 16, 2013 “Modeling the response to medicines in mice with pancreatic cancer”, WTSI, Hinxton, UK

Oct 9, 2013 “Advances in Pancreatic Cancer”, CINJ Grand Rounds

Oct 29, 2013 “Developing Treatments in Pancreatic Cancer”, NIH

Nov 5, 2013 “Modeling Pancreatic Cancer Biology and Medicine”, Keynote: AACR conference, model organisms. San Diego

Nov 19, 2013 “Treating pancreatic cancer”, NCI workshop. Boston, MA

Nov 20, 2013 “Pancreatic Cancer Therapies: Overcoming Resistance”, BIDMC. Boston, MA

January 9, 2014 “Pancreatic Cancer Scientific Progress”, Yale University, New Haven, CT

January 13, 2014 “New model systems to study pancreatic cancer”, SALK Institute, San Diego, CA.

Feb. 2, 2014 ALPS meeting, “Pancreatic Cancer Organoids” Madonna di Campiglia, Italy

March 9, 2014 “Progress in pancreatic cancer”, Helmholtz Assoc, Kloster Seeon, Germany

March 25, 2014 “Pancreatic Ductal Organoids”, NCI Shady Grove Campus, Washington, DC

March 26, 2014 “Progress in Pancreatic Cancer Modeling”, Princeton University, NJ

April 8, 2014 “Pancreatic cancer”, AACR Annual Meeting, 2014, San Diego, CA

April 16, 2014 “Pancreatic Cancer Models” University of Colorado, Denver, CO

April 29, 2014 “Pancreatic cancer organoids resolve fundamental questions and identify therapies”, Princeton University, NJ

May 8, 2014 “Molecular regulation of aging of normal and cancer stem cells” EMBL, Heidelberg, Germany

May 18, 2014 Innovations in Research and Treatment, AACR Special Conference on Pancreatic Cancer, New Orleans, LA

June 2, 2014 NIH Reproducibility Workshop, NIH, Washington, DC

June 26, 2014 “What we can learn from models of pancreatic cancer?”, EPC & IAP, Southampton, UK

July 1, 2014 “Treating Pancreatic Cancer”, Les Treilles Foundation, Niece, France

July 4, 2014 “Mice and Man”, International Symposium on Pancreas Cancer 2014, Verona, Italy

August 22, 2014 “Pancreatic Cancer Treatment Strategies”, JAX, Bangor, ME

September 9, 2014 “Modeling Pancreatic Cancer Medicine”, Icahn School of Medicine, Mount Sinai, NY

October 22, 2014 “Modeling Pancreatic Cancer Medicine” University of Chicago, IL

November 14, 2014 “Pancreatic cancer organoids resolve fundamental questions and identify therapies”, Royal Institute for the Tropics, Amsterdam

February 18, 2015 “Pancreatic cancer models for medicine”, Thomas Jefferson University, Philadelphia, PA

February 24, 2015 “New models for pancreatic treatment”, MD Anderson Cancer Center, Texas

March 11, 2015 “Pancreatic cancer models and medicine”, UC San Diego, Moores Cancer Center, California

March 16, 2015 “Modeling pancreatic cancer medicine”, MIT Koch Institute, Cambridge, MA

March 24, 2015 “New models for pancreatic cancer treatment”, Fred Hutchinson Cancer Research Center, Seattle, WA

April 17, 2015 “Redox and Mitochondrial Regulation in KRAS Oncogenesis. Titisee, Germany

May 18, 2015 “Redox and Mitochondrial Regulation in Pancreatic Cancer”, Monte Verita, Ascona Switzerland
 May 20, 2015 “Pancreatic Cancer Models and Medicine”, CC BIO, Bergen Norway
 July 1, 2015 “Biology and Treatment of Pancreatic Cancer”, University of Salerno, Italy
 August 21, 2015 “Pancreatic Cancer Treatment Strategies”, JAX Labs, Bangor, ME
 September 3, 2015 “Redox Regulation in Pancreatic Cancer”, CCBI, Helsinki, Finland
 September 17, 2015 “Pancreatic Cancer Models for Medicine”, Utrecht PC symposium, NE
 September 25, 2015 Lori Memorial Lecture: “Pancreatic Cancer Biology and Therapy”, WUSL
 October 22, 2015 “Basic and Translational Approaches using PC organoids”, Titisee, DE
 October 28, 2015 “Modeling and Manipulating Pancreatic Cancer”, AFRCP Marseille, FR
 November 7, 2015 “Kras dependency in PC”, AACR-EORTC, Boston
 December 16, 2015 “Kras redox dependency in PC”, NCI Ras symposium, Frederick
 March 4, 2016 “Organoid models for improving care of PC patients”, SUNY Downstate
 March 5, 2016 “PC models and medicine”, SSO keynote, Boston
 April 8, 2016 “Organoid models of PC”, Governor’s Conf: Institute for Advanced Study
 April 12, 2016 “Organoid models of PC”, UNC cancer symposium
 April 16, 2016 “Insights from studies of PC organoids”, ASCI/AAP, Chicago
 April 18, 2016 “Modeling the PC Stroma”, AACR New Orleans
 April 27, 2016 “PC Models and Medicine”, MGH grand rounds
 May 14, 2016 AACR Pancreatic Cancer Meeting, Orlando
 May 25, 2016 Pancreatic Cancer Organoids, Johns Hopkins, MD
 July 2, 2016 Stromal Biology and Therapy in PDAC, Shanghai
 July 7, 2016 How to cure Pancreatic Cancer, Liverpool EPC meeting
 October 19, 2016 Detecting and Killing Pancreatic Cancer, ESGCT-ISSCR, Florence
 April 6, 2017 Pancreatic Cancer, MUSC
 April 12, 2017 Pancreatic Cancer Stroma AACR
 April 10, 2017 Pancreatic Cancer Medicine Univ. Arkansas
 Sept 22, 2017 Pancreatic Cancer Medicine, UVA
 September 26, 2017 Pancreatic Cancer Mouse Models, AACR, Orlando
 Nov 10, 2017 Forbeck Meeting on Ras and Myc, Lake Geneva WI
 Feb 14 PC Biology and Medicine, HCI, Univ Utah
 March 6 PC Biology and Medicine, Moffitt Cancer Center, FL
 March 26, 2018 Defeating PC, Fox Chase Cancer Center Distinguished Lecture, PA
 March 28 PC Biology and Medicine Univ VA
 April 9 Personalizing the care of PC patients to chemotherapy. Columbia U
 April 11 Personalizing the care of PC patients. SWOG Plenary, San Francisco
 April 14 AACR Meet the Experts Session: PC Microenvironment
 April 19 PC Biology and Medicine Beene Keynote Lecture, MSKCC retreat
 May 11 Predictive Models for the Treatment of PC, Princeton
 May 15, 2018 PC Biology and Medicine, Fred Hutchinson, Seattle
 May 29 PC Biology and Medicine Weismann Institute, Israel
 June 13, Costa Memorial Lecture PC Biology and Medicine, Uni Chicago
 June 15, 2018 Evergrande Symposium, PC Biology and Medicine, Harvard
 June 21, 2018 Ronald Herberman Keynote Lecture, U Pittsburgh
 June 25, 2018 Improving PC response to therapy, Pezcoller Foundation, Trento Italy
 August 18, 2018 “Models of Human Pancreatic Cancer Biology and Medicine” JAX Labs, ME

August 19, 2018	"Pancreatic Cancer Heterogeneity" Gordon Research, Kingston, RI
September 12, 2018	"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer" EMBL Symp., Heidelberg, Germany
September 27, 2018	"Improving treatment of pancreatic cancer" MSKCC, New York
October 15, 2018	"Pancreatic Cancer Biology and Medicine", The Ohio State University, Ohio
October 26, 2018	Pancreatic Cancer Biology and Medicine, Keynote, Mayo Clinic Conf., Scottsdale, AZ
October 30, 2018	"Fibroblast Heterogeneity in Solid Tumors: Implications for Pancreatic Cancer", Harvard University, Boston
November 1, 2018	"Fibroblast Heterogeneity in Pancreatic Cancer", WGF Foundation, CO
December 11, 2018	"Pancreatic Cancer Models and Medicine", Salk Inst., La Jolla, CO
February 7, 2019	"Organoid based pancreatic cancer trial design", ALPS, Italy

Editorial responsibilities

<i>Date</i>	<i>Journal name (ad hoc reviewer vs Editorial Board with position as applicable)</i>
2004-2009	Associate Editor: Cancer Research
2010-	Scientific Editor, Cancer Discovery
2011-2013	Editor, Oncogene
2012-	Academic Editor, JEM

Study section peer review activities

<i>Date</i>	<i>Activity</i>
Feb 2016-	NCI-NIH TCB Ad Hoc, repeat reviewer
Feb 2008	NIH-NCI, MONC study section Ad-Hoc reviewer
2006-	CRUK, ERC, AICR, EU FP7, AIRC, MRC, WT, ISF
2010-	Stand-up to Cancer Scientific Review Committee (Pancreatic, prostate cancer, new Convergence grant for Pancreatic cancer)
2004-	AACR, Lustgarten

Other consultant activities or positions

<i>Date</i>	<i>Activity</i>
10/27/2000	Co-inventor, "Treatment of Gastrointestinal Stromal Tumors". US application #60/243,810.
1/23/2009	Co-inventor, "Hedgehog pathway inhibitors". Filed by CRT/CRUK Jan 23 rd 2009 as US61/205,837 (Olive et al, 2009); and PCT US2010/021816 filed January 22, 2010.

L. BIBLIOGRAPHY

1. Peer-Reviewed Articles

Tuveson DA, Ahearn JA, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR 2/CD19 complex. *J Exp Med* 1991 May 1;173(5):1083-9. PMID: 1708808.

Carter RH, **Tuveson DA**, Park DJ, Rhee SG, Fearon DT. The CD19 complex of B lymphocytes: activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. *J Immunol* 1991; Dec 1;147(11):3663-71. PMID: 1719083.

Matsumoto AK, Kopicky-Burd J, Carter RH, **Tuveson DA**, Tedder TF, Fearon DT. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte containing complement receptor type 2 and CD19. *J Exp Med* 1991; Jan 1;173(1):55-64. PMID: 1702139.

Dal Porto J, Johansen T, Catipovic B, Parfit D, **Tuveson DA**, Gether U, Kozlowski S, Fearon DT, Schneck J. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. *Proc Natl Acad Sci USA* 1993 Jul 15;90(14):6671-5. PMID: 8341685.

Tuveson DA, Carter RH, Soltoff SP, Fearon DT. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. *Science* 1993 May 14;260(5110):986-9. PMID: 7684160.

Johnson L, Mercer KL, Greenbaum D, Bronson RT, Crowley D, **Tuveson DA**, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature* 2001 Apr 26;410(6832):1111-6. PMID: 11323676.

Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, **Tuveson D**, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. *New England Journal of Medicine* 2001 Apr 5;344(14):1052-6. PMID: 11287975.

Tuveson DA, Willis NA, Jacks T, Singer S, Fletcher CDM, Fletcher JA, Demetri GD. STI571 inhibition of c-Kit oncoprotein in Gastrointestinal Stromal Tumors: biological and clinical implications. *Oncogene* 2001 Aug 16;20(36):5054-8. PMID: 11526490.

Jackson EL, Willis NA, Mercer KL, Crowley D, Bronson RT, Jacks T, **Tuveson DA**. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes and Development* 2001 Dec 15;15(24):3243-8 PMID: 11751630.

Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen C, Xiao S, **Tuveson DA**, Demetri GD, Fletcher CDM, Fletcher JA. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. *Cancer Research* 2001 Nov 15;61(22):8118-21. PMID: 11719439.

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, **Tuveson DA**, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *New England Journal of Medicine*. 2002 Aug 15;347(7):472-80. PMID: 12181401

Hingorani SR, Jacobetz, MA, Robertson GP, Herlyn M, **Tuveson DA**. Suppression of BRAFV599E in human melanoma abrogates transformation. *Cancer Research* 2003 Sep 1;63(17):5198-202. PMID: 14500344.

Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CVE, Hruban RH, Lowy AM, **Tuveson DA**. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003 Dec;4(6):437-50. PMID: 14706336.

Aguirre AJ, Bardeesy N, Sinha M, Lopez L, **Tuveson DA**, Horner J, Redston MS, DePinho RA. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma in the mouse. *Genes and Development* 2003 Dec 15;17(24):3112-26. Epub 2003 Dec 17. PMID: 14681207.

Braun BS, **Tuveson DA**, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. *Proc Natl Acad Sci (USA)*, 2004 Jan 13;101(2):597-602. Epub 2003 Dec 29. PMID: 14699048.

Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, **Tuveson DA**, Jacks T, Gilliland DG. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. *J Clin Invest*, 2004 Feb;113(4):528-38. PMID: 14966562.

Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. Endogenous oncogenic *Kras*^{G12D} stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell*, 2004 Apr;5(4):375-87. PMID: 15093544.

Olive, KP, **Tuveson DA**, Ruhe ZC, Yin R, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant *p53* 'Gain-of-Function' in Two Mouse Models of Li-Fraumeni Syndrome. *Cell*, 2004 Dec 17;119(6):847-60. PMID: 15607980.

Sharma A, Trivedi NR, Zimmerman MA, **Tuveson DA**, Smith CD, Robertson GP. Mutant V599E BRAf regulates growth and vascular development of malignant melanoma tumors. *Cancer Research*, 2005 Mar 15;65(6):2412-21. PMID: 15781657.

Hingorani, SR, Wang L, Deramautd TB, Combs C, Multani A, Hruban RH, Rustgi AK, Chang S, **Tuveson DA**. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell*, 2005 May;7(5):469-83. PMID: 15894267.

Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, **Tuveson DA**, Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. *Cancer Cell*, 2005 Oct;8(4):311-21. PMID: 16226706.

Wijnhoven SWP, Zwart E, Speksnijder EN, Beems RB, Oliver KP, **Tuveson DA**, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. *Cancer Research*, 2005 Sep 15;65(18):8166-73. PMID: 16166291.

Tuveson DA, Zhu L, Gopinathan A, Willis NA, Kachatrian L, Grochow R, Pin CL, Mitin NY, Taparowsky EL, Gimotty PA, Hruban RH, Jacks T, Konieczny SF. Mist1-Kras^{G12D} knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. *Cancer Research*, 2006 Jan 1;66(1):242-7. PMID: 16397237.

Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Klöppel G, Lauwers GY, Longnecker DS, Lüttges J, Maitra A, Offerhaus GJ, Pérez-Gallego L, Redston M, **Tuveson DA**. Pathology of Genetically Engineered Mouse Models of Pancreatic Cancer: Consensus Report and Recommendations. *Cancer Research*, 2006 Jan 1;66(1):95-106. PMID: 16397221.

King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, Kumar R, Rusnak DW, Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Loughheed JC, Lee J, Chau D, Stout TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor RG, Smalley KS, Herlyn M, Morrissey MM, **Tuveson DA**, Huang PS. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. *Cancer Research*, 2006 Dec 1;66(23):11100-5. PMID: 17145850.

Braun BS, Archard JA, Van Ziffle JA, **Tuveson DA**, Jacks TE, Shannon K. Somatic activation of a conditional Kras^{G12D} allele causes ineffective erythropoiesis in vivo. *Blood*. 2006 Sep 15;108(6):2041-4. Epub 2006 May 23. PMID: 16720837.

Ventura A, Kirsch DG, McLaughlin ME, **Tuveson DA**, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. Restoration of p53 function leads to tumour regression in vivo. *Nature*. 2007 Feb 8;445(7128):661-5. Epub 2007 Jan 24. PMID: 17251932.

Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, **Tuveson DA**, Jaenisch R, Jacks T. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. *Genes and Development*. 2007 Mar 15;21(6):694-707. PMID: 17369402.

Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, **Tuveson DA**, Hingorani SR. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. *Cancer Cell*. 2007 Mar;11(3):229-43. PMID: 17349581.

Zhang J, Liu Y, Beard C, **Tuveson DA**, Jaenisch R, Jacks TE, Lodish HF. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. *Blood*. 2007 Jun 15;109(12):5238-41. Epub 2007 Feb 22. PMID: 17317860.

Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, **Tuveson DA**, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. *Cancer Research*. 2007 Jul 1;67(13):6075-82. PMID: 17616662.

Clark CE, Hingorani SR, Mick R, Combs C, **Tuveson DA**, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. *Cancer Research* Oct 1;67(19):9518-27. PMID: 17909062.

Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, **Tuveson DA**, Capobianco AJ, Tybulewicz VL, Jacks T. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. *Cancer Research*. 2007 Sep 1;67 (17):8089-94. PMID: 17804720.

Flaherty KT, Schiller J, Schuchter LM, Liu G, **Tuveson DA**, Redlinger M, Lathia C, Xia C, Petrenciuc O, Hingorani SR, Jacobetz MA, VanBelle P, Elder D, Brose MS, Weber BL, Albertini MR, O'Dwyer PJ. A Phase 1 trial of the oral, multikinase inhibitor sorafenib in combination with Carboplatin and Paclitaxel. *Clin Cancer Research*, 2008; Aug 1;14(15):4836-42. doi: 10.1158/1078-0432.CCR-07-4123. PMID: 18676756.

Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, **Tuveson DA**. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. *Science*. 2009; Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21. PMID: 19460966.

Karreth, FA, DeNicola GM, Winter SP, **Tuveson DA**. C-Raf inhibits MAPK activation and transformation by B-Raf^{V600E}. *Molecular Cell*, 2009. Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017. PMID: 19917255.

Kramam M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, **Tuveson DA**, and Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein- α . *Science*, 2010. Nov 5;330(6005):827-30. doi: 10.1126/science.1195300. PMID: 21051638.

Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, **Tuveson DA**, Venkitaraman AR. Germline Brca2 Heterozygosity Promotes KrasG12D-Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer. *Cancer Cell*. 2010. Nov 16; 18(5):499-509. doi: 10.1016/j.ccr.2010.10.015. Epub 2010 Nov 4. PMID: 21056012.

Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalglish GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA,

Wessels LF, Richard S, Kahnoski RJ, Anema J, **Tuveson DA**, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature*. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19. PMID: 21248752.

Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, **Tuveson DA**, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt- β -catenin signaling to slow tumor progression. *Gastroenterology*. 2011 Oct;141(4):1486-97, 1497.e1-14. doi: 10.1053/j.gastro.2011.06.047. Epub 2011 Jun 24. PMID: 21704588

Pearson HB, Perez-Mancera PA, Dow LE, Ryan A, Tennstedt P, Bogani D, Elsum I, Greenfield A, **Tuveson DA**, Simon R, Humbert PO. SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. *J Clin Invest*. 2011 Nov;121(11):4257-67. doi: 10.1172/JCI58509. Epub 2011 Oct 3. PMID: 21965329

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, **Tuveson DA**, Griffiths JR, Jodrell DI. A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy. *Cancer Chemother Pharmacol*. 2011 Nov; 68(5):1243-53. doi: 10.1007/s 00280-011-1613-0. Epub 2011 Mar 23. PMID: 21431415.

DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, **Tuveson DA**. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature*. 2011 Jul 6;475(7354): 106-9. doi:10.1038/ nature10189. PMID: 21734707.

Karreth FA, Frese KK, DeNicola GM, Baccarini M, **Tuveson DA**. C-Raf is required for the initiation of lung cancer by K-Ras^{G12D}. *Cancer Discovery* 2011 Jul; 1(2):128-36. doi: 10.1158/2159-8290.CD-10-0044. Epub 2011 May 11. PMID: 22043453.

Caldwell ME, DeNicola GM, Martins CP, Jacobetz MA, Maitra A, Hruban RH, **Tuveson DA**. Cellular features of senescence during the evolution ductal pancreatic cancer. *Oncogene*, 2012 Mar 22;31(12):1599-608. doi:10.1038/onc.2011.350. Epub 2011 Aug 22.

Gopinathan A, Denicola GM, Frese KK, Cook N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T, **Tuveson DA**. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. *Gut*, 2011 Jun; 61(6):877-84. doi: 10.1136/gutjnl-2011-300850. Epub 2011 Dec 9. PMID: 22157328.

Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, **Tuveson DA**, Hagemann T. Crosstalk between the canonical NF- κ B and Notch signaling pathways inhibits Ppar γ expression and promotes pancreatic cancer progression in mice. *J Clin Invest*. 2011 Dec;121(12):4685-99. doi: 10.1172/JCI45797. Epub 2011 Nov 7. PMID: 22056382.

Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, Krauthammer M, Halaban R, Provero P, Adams DJ, **Tuveson DA**, Pandolfi PP. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. *Cell*. 2011 Oct 14;147(2):382-95. doi: 10.1016/j.cell.2011.09.032. PMID: 22000016.

Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, **Tuveson DA**, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt- β -catenin signaling to slow tumor progression. *Gastroenterology*. 2011 Oct;141(4):1486-97, 1497.e1-14. doi: 10.1053/j.gastro.2011.06.047. Epub 2011 Jun 24. PMID: 21704588.

Brais RJ, Davies SE, O'Donovan M, Simpson BW, Cook N, Darbonne WC, Chilcott S, Lolkema MP, Neesse A, Lockley M, Corrie PG, Jodrell DI, Prasad RK, Huguet EL, Jah A, Jamieson NV, de Sauvage FJ, **Tuveson DA**, Carroll NR. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. *Pancreatology*, 2012 Jan-Feb;12(1):8-15. doi: 10.1016/j.pan.2011.12.009. Epub 2011 Dec 31. PMID: 22487467.

Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, **Tuveson DA**. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. *J Exp Med*. 2012, Mar 12;209(3):437-44. doi: 10.1084/jem.20111923. Epub 2012 Feb 20. PMID: 22351932.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, **Tuveson DA**. *nab*-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. *Cancer Discovery* 2012. Mar;2(3):260-9. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28. PMID: 22585996 .

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, **Tuveson DA**. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. *GUT* 2013 Jan; 62(1): 112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30. PMID: 22466618.

Neesse A, Hahnenkamp A, Griesmann H, Buchholz M, Hahn SA, Maghnoij A, Fendrich V, Ring J, Sipos B, **Tuveson DA**, Bremer C, Gress TM, Michl P. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. *GUT* 2013 Jul;62(7):1034-43.2012 Jun 7. [Epub ahead of print] PMID: 22677720

Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grützmann R, Aust D, Rümmele P, Knösel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ, **Tuveson DA**. The deubiquitinase *USP9X* suppresses pancreatic ductal adenocarcinoma. *Nature* 2012 Apr 29;486(7402):266-70. doi: 10.1038/nature11114. PMID: 22699621.

Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, **Tuveson DA**, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012 Nov 15;491(7424):399-405. doi: 10.1038/nature11547. Epub 2012 Oct 24. PMID: 23103869

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, **Tuveson DA**. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proc Natl Acad Sci U S A*. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8. PMID: 23836645

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, **Tuveson DA**. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice. *Gut*. 2013 Sep 25. doi: 10.1136/gutjnl-2013-305559. [Epub ahead of print]. PMID: 24067278

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, **Tuveson DA**, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci USA*. 2013 Nov 25. [Epub ahead of print]. PMID: 24277834

Mara H, Sherman, Ruth T. Yu, Dannielle D. Engle, Ning Ding, Annette R. Atkins, Herve Tiriatic, Eric A. Collisson, Frances Connor, Terry Van Dyke, Serguei Kozlov, Philip Martin, Tiffany W. Tseng, David W. Dawson, Timothy R. Donahue, Atsushi Masamune, Tooru Shimosegawa, Minoti V. Apte, Jeremy S. Wilson, Beverly Ng, Sue Lynn Lau, Jenny E. Gunton, Geoffrey M. Wahl, Tony Hunter, Jeffrey A. Drebin, Peter J. O'Dwyer, Christopher Liddle, David A. Tuveson, Michael Downes, Ronald M. Evans. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy. *Cell*. 2014 Sep 25;159: 80–93. PMID: 25259922

Sylvia F. Boj*, Chang-Il Hwang*, Lindsey A. Baker*, Iok In Christine Chio*, Dannielle D. Engle*, Vincenzo Corbo*, Myrthe Jager*, Mariano Ponz-Sarvise, Hervé Tiriatic, Mona S. Spector, Ana Gracanin, Tobiloba Oni, Kenneth H. Yu, Ruben van Boxtel, Meritxell Huch, Keith D. Rivera, John P. Wilson, Michael E. Feigin, Daniel Öhlund, Abram Handly-Santana, Christine M. Ardito-Abraham, Michael Ludwig, Ela Elyada, Brinda Alagesan, Giulia Biffi, Georgi N. Yordanov, Bethany Delcuze, Brianna Creighton, Kevin Wright, Youngkyu Park, Folkert H.M. Morsink, I. Quintus Molenaar, Inne H. Borel Rinkes, Edwin Cuppen, Yuan Hao, Ying Jin, Isaac J. Nijman, Christine Iacobuzio-Donahue, Steven D. Leach, Darryl J. Pappin, Molly Hammell, David S. Klimstra, Olca Basturk, Ralph H. Hruban, George Johan Offerhaus, Robert G.J. Vries, Hans Clevers, **David A. Tuveson**. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. *Cell*, 2014 Dec 31. pii: S0092-8674(14)01592-X. doi: 10.1016/j.cell.2014.12.021. [Epub ahead of print]. PMID: 25557080.

Palm W, Park Y, Wright K, Pavlova NN, **Tuveson DA**, Thompson CB. The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1. *Cell*, 2015 Jul 16;162(2):259-70. doi: 10.1016/j.cell.2015.06.017. Epub 2015 Jul 2. PMID: 26144316

Iok In Christine Chio, Seyed Mehdi Jafarnejad, Mariano Ponz-Sarvise, Youngkyu Park, Keith Rivera, Wilhelm Palm, John Wilson, Vineet Sangar, Yuan Hao, Daniel Öhlund, Kevin Wright, Dea Filippini, Eunjung Lee, Brandon Da Silva, Christina Schoepfer, John Erby Wilkinson, Jonathan Buscaglia, Gina M. DeNicola, Herve Tiriatic, Molly Hammell, Howard C. Crawford, Edward E. Schmidt, Craig B. Thompson, Darryl J. Pappin, Nahum Sonenberg, **David A. Tuveson**. NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. *Cell*, 2016 Jul 27. pii: S0092-8674(16)30864-9. doi: 10.1016/j.cell.2016.06.056. [Epub ahead of print]. PMID: 27477511

Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, **Tuveson DA**, Campbell F, Schmid MC, Mielgo A. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. *Cancer Res*. 2016 Dec 1;76(23):6851-6863. doi: 10.1158/0008-5472.CAN-16-1201. Epub 2016 Oct 14. PMID: 27742686

Senturk S, Shirole NH, Nowak DG, Corbo V, Pal D, Vaughan A, **Tuveson DA**, Trotman LC, Kinney JB, Sordella R. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. *Nat Commun*. 2017 Feb 22;8:14370. doi: 10.1038/ncomms14370. PMID: 28224990

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriatic H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, **Tuveson DA**. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *J Exp Med*. 2017 Mar 6;214(3):579-596. doi: 10.1084/jem.20162024. Epub 2017 Feb 23. PMID: 28232471

Feigin ME, Garvin T, Bailey P, Waddell N, Chang DK, Kelley DR, Shuai S, Gallinger S, McPherson JD, Grimmond SM, Khurana E, Stein LD, Biankin AV, Schatz MC, **Tuveson DA**. Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. *Nat Genet*. 2017 Jun;49(6):825-833. doi: 10.1038/ng.3861. Epub 2017 May 8. PMID: 28481342

Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, Maiorino L, Tiriack H, Young CM, Miyabayashi K, Filippini D, Creighton B, Burkhart RA, Buscaglia JM, Kim EJ, Grem JL, Lazenby AJ, Grunkemeyer JA, Hollingsworth MA, Grandgenett PM, Egeblad M, Park Y, **Tuveson DA**, **Vakoc CR**. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. *Cell*. 2017 Aug 24;170(5):875-888.e20. doi: 10.1016/j.cell.2017.07.007. Epub 2017 Jul 27. PMID:28757253

2. Invited Editorials and Reviews

Tuveson DA, Weber BL, Herlyn H. BRAF as a potential target in melanoma and other malignancies. *Cancer Cell*, 2003 Aug; 4(2):95-8. PMID: 12957284.

Tuveson DA, Jacks T. Modeling human lung cancer in mice: similarities and shortcomings. *Oncogene* 1999 Sep 20;18(38):5318-24. PMID: 10498884.

Tuveson DA and Fletcher JA. Signal Transduction pathways in sarcoma as targets for therapeutic intervention. *Current Opinion in Oncology* 2001 Jul; 13(4):249-55. PMID: 11429482.

Tuveson DA and T Jacks. Technologically advanced cancer modeling in mice. *Current Opinion Genetics & Development* 2002 Feb;12(1):105-10. PMID: 11790563.

Hingorani SR and Tuveson DA. Ras redux: rethinking how and where Ras acts. *Current Opinion in Genetics and Development* 2002 Feb;13(1):6-13. PMID: 12573429.

Hingorani SR and Tuveson DA. In search of an early warning system for pancreatic cancer. *Cancer Biology and Therapy* 2003 Jan-Feb;2(1):84-6. PMID: 12673125.

Hingorani SR and Tuveson DA. Targeting oncogene dependence and resistance. *Cancer Cell* 2003 May;3(5):414-7. PMID: 12781357.

Wang LF, Hingorani SR, Tuveson DA. Detecting and diagnosing ampullary neoplasms. *Cancer Biology and Therapy*, 2004 Jul;3(7):657-9. Epub 2004 Jul 20. PMID: 15326385.

Karreth F, Tuveson DA. Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis. *Cancer Biology and Therapy*, 2004 Nov;3(11):1058-9. Epub 2004 Nov 12. PMID: 15640618.

Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. *Cold Spring Harb Symp Quant Biol*. 2005;70:65-72. PMID: 16869739.

Hruban RH, Rustgi, AK, Brentnall TA, Tempero MA, Wright CV, and Tuveson DA. Pancreatic cancer in mice and man: the Penn workshop 2004. *Cancer Research*, 2006 Jan 1;66(1):14-7. PMID: 16397208.

Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. *Clinical Cancer Research*. 2006 Sep 15;12(18):5277-87. PMID: 17000660.

Frese KK, Tuveson DA. Maximizing mouse cancer models. *Nature Reviews Cancer*. 2007 Sep;7(9):645-58. Review. PMID: 17687385.

Cook N, Olive KP, Frese K, Tuveson DA. K-Ras driven pancreatic cancer mouse model for anticancer inhibitor analyses. *Methods Enzymology*. 2008 ;439:73-85. doi: 10.1016/S0076-6879(07)00406-5. PMID: 18374157.

Gopinathan A, Tuveson DA. The use of GEM models for experimental cancer therapeutics. *Dis Model Mech*. 2008 Sep-Oct;1(2-3):83-6. doi: 10.1242/dmm.000570. PMID: 19048065.

Karreth FA, Tuveson DA. Modelling oncogenic Ras/Raf signalling in the mouse. *Curr Opin Genet Dev*. 2009 Feb;19(1):4-11. doi: 10.1016/j.gde.2008.12.006. Epub 2009 Feb 7. PMID: 19201597.

Caldwell ME, Tuveson DA. Finding and killing the CRABs of pancreatic cancer. *Gastroenterology*. 2009 Sep;137(3):782-5. doi: 10.1053/j.gastro.2009.07.035. Epub 2009 Jul 28. PMID: 19643193.

DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. *Eur J Cancer*. 2009 Sep; 45 Suppl 1:211-6. doi: 10.1016/S0959-8049(09)70036-X. PMID: 19775620.

Grippio PJ, Tuveson DA. Deploying Mouse Models of Pancreatic Cancer for Chemo-prevention Studies. *Cancer Prev Res*. 2010 Nov;3 (11):1382-7. doi: 10.1158/1940-6207.CAPR-10-0258. Epub 2010 Nov 2. PMID: 21045161.

Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. *Gut*, 2011 Jun;60(6):861-8. Epub 2010 Oct 21. PMID: 20966025.

Tuveson D, Hanahan D. Translational medicine: Cancer lessons from mice to humans. *Nature*. 2011 Mar 17;471(7338):316-7. PMID: 21412332.

Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. *Drug Discov Today*. 2012 Mar;17(5-6):253-60. PMID: 22493784.

Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. *Gastroenterology*. 2012 May;142(5):1079-92. doi: 10.1053/j.gastro.2012.03.002. Epub 2012 Mar 8. PMID: 22406637.

Tuveson DA, Neoptolemos JP. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. *Cell*. 2012 Jan 20;148(1-2):21-3. doi: 10.1016/j.cell.2011.12. 021. PMID: 22265397.

Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. What we have learned about pancreatic cancer from mouse models. *Gastroenterology*. 2012 May;142(5):1079-92. Epub 2012 Mar 8. Review. PMID: 22406637

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. *Clin Cancer Res*. 2012 Aug 15;18(16):4266-76. PMID: 22896693

Chandel NS, Tuveson DA. The promise and perils of antioxidants for cancer patients. *N Engl J Med*. 2014 Jul 10;371(2):177-8. doi: 10.1056/NEJMcibr1405701. PMID: 25006725

Öhlund D, **Elyada E, Tuveson D**. Fibroblast heterogeneity in the cancer wound. *J Exp Med*. 2014 Jul 28;211(8):1503-23. doi: 10.1084/jem.20140692. Review. PMID: 25071162

Date: _____

Signature: _____